AceLink Therapeutics Received the Acceptance of Investigational New Drug Application from Chinese NMPA
AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that the IND application of company’s lead compound AL01211 was accepted by Chinese National Medical Products Administration (NMPA) and Center for Drug Evaluation (CDE). Dr. Jerry Shen, Chairman, CEO and co-founder of the company said, “this is a big milestone for our young and growing company. AL01211 is a highly specific and potent glucosylceramide synthase inhibitor that is suitable for various non-CNS indications. We are very looking forward to having the clearance and approval from Center for Drug Evaluation (CDE) of NMPA so we can advance to clinical trials in China.”
AceLink Therapeutics Employee awarded the Bronze for The PharmaTimes Clinical Researcher of the Year - The Americas in 2021
Acelink Therapeutics would like to congratulate our team member Jessica Nario for winning the Bronze or third-place award for The PharmaTimes Clinical Researcher of the Year - The Americas (PTCROY) in 2021. Jessica Nario is Associate Director of Clinical Operations, leading several aspects of clinical study conduct including strategic organization and vendor partnerships, clinical study start-up, execution, and closure for Acelink’s lead molecule AL01211 which is now in clinical development within Australia and USA with a potential expansion in Europe. Jessica is an integral member of the team.
AceLink Therapeutics Announced the establishment of AceLink Therapeutics (SuZhou) Co. Ltd.
AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that it has established AceLink Therapeutics China subsidiary at Suzhou Industry Park, China. Dr. Jerry Shen, Chairman, CEO and co-founder of the company said, “we are very excited to have our China company established. This new entity will allow us to interact closely with our local partners, conduct clinical trials in China and recruit local talents to advance our research and development programs. Our mission is to bring products to China market to help Chinese patients with unmet medical needs and to bring the drug candidates developed in China to the global market”.
AceLink Therapeutics Announced Dosing First Human Subject in a Phase I Clinical Trial
with its GCS inhibitor AL01211
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for kidney diseases, today announced dosing the first human subject in its Phase I clinical trial evaluating AL01211, a novel small molecule glucosylceramide synthase (GCS) inhibitor.